Get the Stockscreener App
10.23
3.65%
0.36
After Hours:
10.23
Certara Inc stock is traded at $10.23, with a volume of 1.89M.
It is up +3.65% in the last 24 hours and down -14.61% over the past month.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.
See More
Previous Close:
$9.87
Open:
$9.73
24h Volume:
1.89M
Relative Volume:
1.50
Market Cap:
$1.59B
Revenue:
$363.55M
Net Income/Loss:
$-78.68M
P/E Ratio:
-20.46
EPS:
-0.5
Net Cash Flow:
$50.74M
1W Performance:
+0.79%
1M Performance:
-14.61%
6M Performance:
-10.03%
1Y Performance:
-39.65%
1-Day Range:
$9.73
$10.31
1-Week Range:
$9.53
$10.31
52-Week Range:
$9.41
$19.18
Certara Inc Stock (CERT) Company Profile
Name
Certara Inc
Sector
Industry
Phone
(415) 237-8272
Address
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Compare CERT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
10.23 | 1.59B | 363.55M | -78.68M | 50.74M | -0.50 |
|
VEEV
Veeva Systems Inc
|
226.54 | 37.08B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
57.95 | 10.64B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
49.89 | 8.13B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
88.74 | 7.54B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
37.33 | 6.36B | 906.14M | -52.62M | 89.62M | -0.3621 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-27-25 | Initiated | TD Cowen | Buy |
| Sep-27-24 | Upgrade | UBS | Neutral → Buy |
| Apr-10-24 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Apr-04-24 | Initiated | JMP Securities | Mkt Perform |
| Feb-26-24 | Initiated | Leerink Partners | Market Perform |
| Dec-07-23 | Initiated | UBS | Neutral |
| Dec-05-23 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Aug-22-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-10-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Apr-12-23 | Initiated | Stephens | Overweight |
| Apr-03-23 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-14-22 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-08-22 | Initiated | Berenberg | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Outperform |
| Jul-01-22 | Initiated | Piper Sandler | Overweight |
| Jan-11-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-05-21 | Resumed | Credit Suisse | Neutral |
| Jul-23-21 | Initiated | Robert W. Baird | Outperform |
| Mar-03-21 | Initiated | Barclays | Overweight |
| Jan-06-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Credit Suisse | Neutral |
| Jan-05-21 | Initiated | Jefferies | Hold |
| Jan-05-21 | Initiated | William Blair | Outperform |
View All
Certara Inc Stock (CERT) Latest News
Checking Back In On Certara: Unattractive Valuation (NASDAQ:CERT) - Seeking Alpha
Certara Expands the Simcyp™ Simulator Platform Advancing Biopharmaceutics, Drug-Drug Interaction & Biologic Capabilities - The Manila Times
Certara unveils advanced drug development simulator - Investing.com
Revolutionary AI Update: How Certara's New Simcyp Platform is Transforming Drug Development - Stock Titan
Proficio Capital Partners LLC Buys Shares of 13,856 Certara, Inc. (NASDAQ:CERT) - Defense World
Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching - simplywall.st
At US$9.91, Is Certara, Inc. (NASDAQ:CERT) Worth Looking At Closely? - Yahoo Finance
Cautious Spending By Large Biopharma Client Dragged Certara (CERT) in Q3 - MSN
Certara Inc.: Is The Biosimulation & Software Growth Here To Stay? - Smartkarma
Commit To Buy Certara At $7.50, Earn 14.3% Annualized Using Options - Nasdaq
Raymond James Financial Inc. Takes Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Certara, Inc. (NASDAQ:CERT) Receives $15.83 Consensus Price Target from Brokerages - Defense World
Certara, Inc. (NASDAQ:CERT) Shares Purchased by HighTower Advisors LLC - Defense World
Avantax Advisory Services Inc. Sells 17,660 Shares of Certara, Inc. (NASDAQ:CERT) - Defense World
Charles Schwab Investment Management Inc. Grows Holdings in Certara, Inc. (NASDAQ:CERT) - Defense World
PNC Financial Services Group Inc. Raises Stock Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Amundi Raises Holdings in Certara, Inc. (NASDAQ:CERT) - Defense World
Atria Investments Inc Reduces Position in Certara, Inc. (NASDAQ:CERT) - Defense World
US Bancorp DE Has $101,000 Stock Position in Certara, Inc. (NASDAQ:CERT) - Defense World
(CERT) Technical Data - news.stocktradersdaily.com
Proficio Capital Partners LLC Takes Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Certara’s SWOT analysis: ai-driven biosimulation firm faces growth challenges By Investing.com - Investing.com South Africa
Certara’s SWOT analysis: ai-driven biosimulation firm faces growth challenges - Investing.com Australia
Certara at Barclays Healthcare: Strategic Shift Toward Biosimulation - Investing.com India
Certara at Barclays Healthcare: Strategic Shift Toward Biosimulation By Investing.com - Investing.com South Africa
Certara Inc (NASDAQ: CERT) – Analysts’ Revisions Point To Positive Sentiment - Stocks Register
Bank of New York Mellon Corp Purchases 1,253,385 Shares of Certara, Inc. (NASDAQ:CERT) - Defense World
23,568 Shares in Certara, Inc. (NASDAQ:CERT) Acquired by Private Advisor Group LLC - Defense World
Certara, Inc. (CERT): Among the Cash-Rich Small Cap Stocks To Invest In According To Analysts - Insider Monkey
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions - citybiz
Certara announces leadership change in drug development By Investing.com - Investing.com South Africa
Certara announces leadership change in drug development - Investing.com India
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 05:07 pm EST - Marketscreener.com
Certara Announces Leadership Change with Dr. Smith’s Departure - TipRanks
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 04:16 pm EST - Marketscreener.com
Certara Appoints Dr. Adrian McKemey as President of Drug Development Solutions -March 05, 2025 at 04:15 pm EST - Marketscreener.com
Can This Former IQVIA Executive Transform Certara's Drug Development Approach? - StockTitan
Principal Financial Group Inc. Has $5.66 Million Stock Position in Certara, Inc. (NASDAQ:CERT) - Defense World
Objective long/short (CERT) Report - Stock Traders Daily
Q2 Earnings Estimate for Certara Issued By William Blair - Defense World
Certara (NASDAQ:CERT) Price Target Raised to $13.00 - Defense World
Q1 Earnings Estimate for Certara Issued By Leerink Partnrs - Defense World
Rhumbline Advisers Has $2.96 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT) - Defense World
Brokerages Set Certara, Inc. (NASDAQ:CERT) Price Target at $15.42 - Defense World
KeyBanc maintains Overweight rating on Certara shares with $15 target - Investing.com India
KeyBanc maintains Overweight rating on Certara shares with $15 target By Investing.com - Investing.com South Africa
Certara Inc Stock (CERT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
2.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):